98753-19-6 Cefpirome sulfate AKSci K518
 
 
Loading Please Wait...
  K518    
Cefpirome sulfate
, 98% (HPLC)
 



IDENTITY
CAS Number:98753-19-6
MDL Number:MFCD08234364
MF:C22H22N6O5S2.H2SO4
MW:612.66
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

REVIEW

 Cefpirome sulfate (HR 810) is a fourth-generation cephalosporin. Trade names include Cefrom, Keiten, Broact, Cefir. Cefpirome is considered highly active against Gram-negative bacteria, including Pseudomonas aeruginosa, and Gram-positive bacteria. Cefpirome exhibits minimal concentration dependent killing and produces prolonged postantibiotic effects only with Staphylococcus aureus Cefpirome sulfate inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs). This inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Currently, Bacteroides fragilis, Enterococci, Pseudomonas spp. and Staphylococci are resistant to cefpirome sulfate, and some Haemophilus spp. and Pneumococci have developed resistance to cefpirome sulfate to varying degrees.

REFERENCES
[1]Lattrell, R.; Duerckheimer, W.; Klesel, N.; Kirrstetter, R.; Seibert, G.; Wieduwilt, M. HR 810, a new parenteral cephalosporin. I. Chemistry and physical properties Edited by Spitzy, K. H.; Karrer, K Proc. Int. Congr. Chemother., 13th (1983), 4, 99/1-99/4.
[2] Kirrstetter, R.; Duerckheimer, W.; Lattrell, R.; Mencke, B.; Scheunemann, K.; Schwab, W.; Seeger, K.; Winkler, I. HR 810, a new parenteral cephalosporin. III. Synthesis and structure-activity relationships in the series of HR 810. Influence of syn-oxime substitution Edited by Spitzy, K. H.; Karrer, K Proc. Int. Congr. Chemother., 13th (1983), 4, 99/9-99/12.
[3] Arai, Susumu; Kobayashi, Shinzo; Hayashi, Shoryo In vitro antibacterial activity of cefpirome sulfate against clinical isolates Chemotherapy (Tokyo) (1991), 39(Suppl. 1), 516-21.
[4] Shiroishi, Hideyuki; Okui, Kiyoshi; Saito, Kenji; Hasegawa, Yoshinari In vitro antibacterial activity of a new cephalosporin, cefpirome Chemotherapy (Tokyo) (1991), 39(Suppl. 1), 522-6.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
K518Cefpirome sulfate
H828Cefpirome

Current as of April 24, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Antibacterials, Cephalosporins


PubChem
  @PubMed